Watchlist Price Alert

Valneva SE (VALN)

NASDAQ: VALN · Real-Time Price · USD

5.82

0.07 (1.22%)

At close: Jun 27, 2025, 3:59 PM

5.80

-0.34%

After-hours: Jun 27, 2025, 04:00 PM EDT

1.22% (1D)

Bid	5.26
Market Cap	494.89M
Revenue (ttm)	186.06M
Net Income (ttm)	-80.39M
EPS (ttm)	-1.29
PE Ratio (ttm)	-4.51
Forward PE	-9.71
Analyst	Buy

Ask	6.98
Volume	25,036
Avg. Volume (20D)	75,885
Open	5.64
Previous Close	5.75
Day's Range	5.64 - 5.97
52-Week Range	3.62 - 8.66
Beta	1.09

About VALN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VALN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VALN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Valneva SE is scheduled to release its earnings on Aug 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+12.08%

Valneva shares are trading higher after the Brazil... Unlock content with Pro Subscription

3 months ago

+3.63%

Valneva shares are trading higher after reaching an agreement with a local French public health agency to provide 40,000 doses of IXCHIQ.

News

2 weeks ago · reuters.com

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat chikungunya, a virus transmitted by mosquitoes, in people aged 65 and above...

1 month ago · seekingalpha.com

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

Valneva SE (NASDAQ:VALN ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Joshua Drumm - Vice President-Global Investor Relations Thomas Lingelbach - Chief Executive Offic...

1 month ago · seekingalpha.com

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Ixiaro generated roughly €94.1 million in 2024 and remains Valneva's main revenue vertical. D...

1 month ago · reuters.com

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

The European Union's health regulator said on Wednesday it has begun a review of Valneva's chikungunya vaccine after reports of serious adverse events in older adults, including two deaths globally.

2 months ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

NEW YORK CITY, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ:VALN). Such investors are advised...

2 months ago · benzinga.com

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

The Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to Valneva SE's VALN single-dose vaccine Ixchiq for the prevention of disease caused by the chikungunya virus in ind...